SBRT Non-Inferior to Hypofractionated IMRT for Intermediate-Risk Prostate Cancer — and 3x Fewer Visits

Localized intermediate-risk prostate cancer offers men multiple treatment paths with broadly similar cancer outcomes: surgery, moderately hypofractionated intensity-modulated radiation therapy (MH-IMRT), or stereotactic body radiotherapy (SBRT). All are guideline-supported. What differs is treatment burden. MH-IMRT requires 20–28 visits over 4–6 weeks. SBRT delivers the same total dose in 5 fractions over approximately 2 weeks — dramatically fewer visits, with significant quality-of-life implications for working-age patients and for patients in rural areas with limited local radiation oncology access.[1]

The JAMA randomized trial enrolled men with localized intermediate-risk prostate cancer and randomized them to SBRT or MH-IMRT. The co-primary endpoints were patient-reported urinary irritative/obstructive and bowel quality of life at 2 years (via validated patient-reported outcome measures), and disease-free survival. Both were assessed for non-inferiority. SBRT met the non-inferiority margin for both quality-of-life endpoints and for disease-free survival — men receiving SBRT reported no worse urinary or bowel symptoms and were not more likely to experience cancer recurrence or progression at 2-year follow-up.[1]

The acute toxicity pattern differed somewhat: SBRT produced slightly higher rates of acute urinary and rectal side effects in the first 3–6 months (a known consequence of larger per-fraction doses), but these resolved to baseline levels comparable to MH-IMRT by 12–24 months. Sexual function outcomes were similar between arms. The non-inferiority finding for disease-free survival is important: it confirms that the compressed fractionation schedule does not sacrifice cancer control.[1]

Clinical Context

Radiotherapy for localized intermediate-risk prostate cancer has undergone progressive hypofractionation over the past 15 years — delivering higher doses per fraction over fewer visits while maintaining disease control and acceptable toxicity. The HYPO-RT-PC trial (2019, Lancet) randomized 1,200 patients to conventionally fractionated EBRT (78 Gy in 39 fractions) versus ultrahypofractionated SBRT (42.7 Gy in 7 fractions over 2.5 weeks); failure-free survival was non-inferior at 5 years, but early genitourinary toxicity was higher in the SBRT arm.[2] The PACE-B trial (2019, Lancet Oncology), comparing SBRT (36.25 Gy in 5 fractions) to conventionally or moderately hypofractionated EBRT in low-to-intermediate risk disease, found non-inferiority for biochemical/clinical disease-free survival at 5 years with no significant difference in late genitourinary or gastrointestinal toxicity.[3]

The comparison of SBRT specifically against moderately hypofractionated IMRT (MH-IMRT, 60–70 Gy in 20–28 fractions over 4–6 weeks) — rather than conventional fractionation — is clinically important because MH-IMRT has itself become the dominant radiotherapy standard in most US and European practices. Most patients choosing radiation over surgery are currently offered MH-IMRT, not conventional fractionation. A non-inferiority comparison between SBRT and MH-IMRT is therefore the most treatment-decision-relevant data: it addresses the actual clinical choice being made at multidisciplinary tumor boards daily, not a historical comparator that has been largely retired.[2]

Why It Matters Clinically

Prostate cancer radiation is one of the success stories of hypofractionation research — the recognition that the prostate cancer cell's radiation biology (low α/β ratio) actually favors fewer, larger fractions over many small ones. SBRT takes this principle to its logical extreme. Prior trials (PACE-B, NRG Oncology GU001) had already shown SBRT feasibility; this new JAMA trial strengthens the evidence base for clinical equivalence with the current standard MH-IMRT approach.[2]

Limitations

Median follow-up at the time of reporting was 2 years — adequate to assess early quality of life but too short to detect meaningful differences in biochemical recurrence, distant metastasis, or prostate cancer-specific mortality. Longer follow-up is essential. The trial also excluded high-risk disease, where fractionation choices may differ. Institutional SBRT expertise varies substantially; results may not generalize to lower-volume centers.